SOUL: Oral Semaglutide Cut Major Cardiovascular Events by 14% — and Why That Matters More Than a Weight Figure

What was reported

Reported June 2026. Absolute event rates should be read alongside these relative reductions.

A trial of this size with a hard endpoint is uncommon in this field. Most of what circulates about GLP-1 drugs is weight change over 64 to 72 weeks — a legitimate measure, and a surrogate for the conditions weight drives.

Why this strengthens the oral formulation specifically

Oral semaglutide's approval for weight management rested on the OASIS programme and on SELECT, the cardiovascular outcomes trial for the injectable. SOUL adds outcomes evidence generated with the oral formulation itself rather than inherited from the injectable.

That distinction is the same one that applies to compounded preparations: evidence generated with one formulation does not automatically transfer to another. Oral delivery of a peptide is a genuinely hard pharmacological problem requiring specific formulation technology, and demonstrating that the delivered drug produces outcomes is not a formality.

SOUL closes that gap for oral semaglutide in a way no compounded oral or sublingual product has for any indication.

How to read a 14% relative reduction

Relative risk reduction is the most quotable form of a result and the least informative. A 14% reduction on a high baseline event rate is a substantial absolute benefit; on a low one it is small.

This trial enrolled high-risk patients specifically, which pushes the baseline rate up and makes the absolute benefit larger. But the absolute figures belong beside the relative one, and anyone quoting 14% without them has given you the more impressive half of the finding.

What it does not establish

Benefit in people without type 2 diabetes or without elevated cardiovascular risk. Benefit at weight-management doses in a weight-management population. And nothing at all about compounded oral or sublingual preparations, which appear in no cardiovascular outcomes trial and for which bioavailability is unpublished.

It also does not establish that the oral route is superior to the injectable. It establishes that the oral route produces outcomes benefit, which is a different and more modest claim.

Where it sits against the null results

The same class produced a clean negative result in 2026. EVOKE and EVOKE+ enrolled 3,808 participants over two years to test whether oral semaglutide slowed Alzheimer's disease progression. It did not.

Reading SOUL and EVOKE together is more informative than reading either alone. A plausible mechanism plus an observational signal does not reliably predict a trial result. Where the class has hard-endpoint evidence — cardiovascular, heart failure, sleep apnoea — it is genuinely strong. Where it has mechanism and association, it is a hypothesis.

Where this sits in a decision

For a patient with type 2 diabetes and cardiovascular risk, this is the kind of evidence that should weigh more heavily than a weight-loss percentage. Hard-endpoint data in a large population is the strongest thing available in this field, and there is very little of it.

For a patient choosing between an approved oral at $149 and a compounded injectable at a similar price, it is another element on the approved side of the ledger — not because the compounded product has been shown worse, but because nothing has been shown about it at all.

The class picture, assembled

Read across the hard-endpoint trials and a coherent shape emerges. SELECT established cardiovascular benefit for injectable semaglutide. SUMMIT reported a 38% reduction in a combined endpoint for tirzepatide in obesity-related heart failure with preserved ejection fraction. SURMOUNT-OSA supported an obstructive sleep apnoea indication. SURPASS-CVOT found tirzepatide non-inferior to dulaglutide over roughly 4.5 years in 13,299 participants. SOUL now adds outcomes evidence for the oral formulation.

What unites these is that each measured something that happens to a patient rather than a number on a scale. That is rarer in this field than the volume of coverage suggests, and it is the strongest argument for approved products over compounded ones — not because compounded preparations have been shown worse, but because this entire body of evidence attaches to the approved product at studied doses and does not transfer.

A note on how these results get quoted

SURPASS-CVOT is the instructive case. It found tirzepatide non-inferior to dulaglutide, another GLP-1. Non-inferiority establishes that a treatment does not fall below an accepted comparator by more than a prespecified margin. It does not establish superiority, and it does not by itself demonstrate benefit against no treatment.

The inference many readers draw — that tirzepatide reduces cardiovascular risk — requires an additional step: that dulaglutide's own placebo-controlled benefit transfers. That is a reasonable clinical inference and it is not what the trial measured. The distinction matters commercially, because cardiovascular benefit is a powerful marketing claim and it is being made on the back of a non-inferiority result.

SOUL is a different and stronger case: a reduction against comparator on a hard endpoint in a large high-risk population. Both belong in the picture, and they support claims of different strength.

How to check any claim on this page for yourself

Everything above should be checkable, and most of it is. Trial claims resolve to a registry entry and a peer-reviewed publication; regulatory claims resolve to an agency document; pricing claims resolve to a provider’s own published page read on a stated date.

Where we could not verify something, we say so rather than rounding it into confidence. Every pharmacy relationship on this site carries a reported rather than verified label, because not one provider has named its fulfilling pharmacy and registration class to us. That is the field we would weight most heavily if we had it, and it is the question worth putting first if you can only ask one — because the FDA has proposed excluding tirzepatide from the 503B bulks list, and whether your supply runs through a 503B outsourcing facility or a 503A pharmacy determines your exposure to that decision.

Four checks take about ten minutes between them. Confirm your prescriber holds a current licence in your state, through that state’s medical board rather than through the provider’s own page. Confirm the fulfilling pharmacy is licensed, and registered as a nonresident pharmacy in your state if it ships from elsewhere. Search the pharmacy’s name against FDA warning letters and recall notices, both public. And ask for a certificate of analysis matched to the batch number on your vial.

None of that establishes that the medicine in your hand is safe. It establishes that the parties involved are inside the regulatory system and currently authorised, which is a floor rather than a guarantee. The honest framing is that you are reducing risk rather than eliminating it — and a provider unwilling to give you the names needed to run those checks has told you something worth knowing.